Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott gets clearance for p24 antigen test

This article was originally published in Clinica

Executive Summary

Abbott Laboratories has received US FDA clearance to market HIVAG-1 Monoclonal, its HIV-1 p24 antigen test. The assay, which detects the virus directly, is intended for detecting infection before seroconversion has taken place. It was cleared for both blood-bank screening and prognostic use in HIV-infected patients. The FDA approved Coulter's p24 test in March (see Clinica No 697, p 16).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT087902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel